These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 12027116)

  • 21. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).
    Del Casale A; Sorice S; Padovano A; Simmaco M; Ferracuti S; Lamis DA; Rapinesi C; Sani G; Girardi P; Kotzalidis GD; Pompili M
    Curr Neuropharmacol; 2019; 17(8):710-736. PubMed ID: 30101713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Priapism associated with polypharmacy.
    Seger A; Lamberti JS
    J Clin Psychiatry; 2001 Feb; 62(2):128. PubMed ID: 11247100
    [No Abstract]   [Full Text] [Related]  

  • 26. Augmenting obsessive-compulsive disorder treatment: from brain to mind.
    Ressler KJ; Rothbaum BO
    JAMA Psychiatry; 2013 Nov; 70(11):1129-31. PubMed ID: 24026506
    [No Abstract]   [Full Text] [Related]  

  • 27. Obsessive compulsive disorder.
    Soomro GM
    Clin Evid; 2003 Dec; (10):1172-87. PubMed ID: 15555141
    [No Abstract]   [Full Text] [Related]  

  • 28. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
    Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
    J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining Pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder.
    Cottraux J; Bouvard MA; Milliery M
    Cogn Behav Ther; 2005; 34(3):185-92. PubMed ID: 16201063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obsessive compulsive disorder.
    Soomro GM
    Clin Evid; 2004 Jun; (11):1319-34. PubMed ID: 15652061
    [No Abstract]   [Full Text] [Related]  

  • 31. A review of pharmacologic treatments for obsessive-compulsive disorder.
    Kaplan A; Hollander E
    Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
    Ramasubbu R; Ravindran A; Lapierre Y
    Pharmacopsychiatry; 2000 Nov; 33(6):236-8. PubMed ID: 11147933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder.
    Matsunaga H; Hayashida K; Maebayashi K; Mito H; Kiriike N
    Int J Psychiatry Clin Pract; 2011 Nov; 15(4):263-9. PubMed ID: 22121999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.
    Wheaton MG; Carpenter JK; Kalanthroff E; Foa EB; Simpson HB
    Psychother Psychosom; 2016; 85(5):314-6. PubMed ID: 27513584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients.
    Sumitani S; Harada M; Kubo H; Ohmori T
    Psychiatry Res; 2007 Jan; 154(1):85-92. PubMed ID: 17208418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An update on the pharmacological treatment of obsessive-compulsive disorder.
    Fontenelle LF; Nascimento AL; Mendlowicz MV; Shavitt RG; Versiani M
    Expert Opin Pharmacother; 2007 Apr; 8(5):563-83. PubMed ID: 17376013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.
    D'Amico G; Cedro C; Muscatello MR; Pandolfo G; Di Rosa AE; Zoccali R; La Torre D; D'Arrigo C; Spina E
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):619-23. PubMed ID: 12787848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders.
    Denys D
    Psychiatr Clin North Am; 2006 Jun; 29(2):553-84, xi. PubMed ID: 16650723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A Review and Recommendations of Evidence-Based Treatments for Pediatric Obsessive-Compulsive Disorder].
    Skarphedinsson G; Lauth B; Njardvik U; Ivarsson T
    Laeknabladid; 2016 Apr; 102(4):179-85. PubMed ID: 27197125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obsessive-Compulsive Disorder: Diagnosis and Management.
    Fenske JN; Petersen K
    Am Fam Physician; 2015 Nov; 92(10):896-903. PubMed ID: 26554283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.